This site is intended for health professionals only

Pfizer pulls sitaxentan off market

Pfizer has removed sitaxentan from the market after concerns were raised about liver toxicity associated with the treatment.

The pharmaceutical firm has recommended that no new patients are prescribed sitaxentan and that patients already on the medicine should contact their doctors.

Pfizer said that although liver toxicity is a known side-effect of the endothelin-receptor antagonists, they had observed a new, idiosyncratic and potentially life-threatening reaction to sitaxentan.

Copyright © Press Association 2011

Pfizer